Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis

Recombinant-modified vaccinia virus Ankara (rMVA) is known to elicit potent antitumor immune responses in preclinical models due to its inherent ability to activate the innate immune system and the activation of adaptive responses mediated by the expression of tumor antigens and costimulus-providing...

Descripción completa

Detalles Bibliográficos
Autores principales: Bella, Ángela, Arrizabalaga, Leire, Di Trani, Claudia Augusta, Cirella, Assunta, Fernandez-Sendin, Myriam, Gomar, Celia, Russo-Cabrera, Joan Salvador, Rodríguez, Inmaculada, González-Gomariz, José, Alvarez, Maite, Teijeira, Álvaro, Medina-Echeverz, José, Hinterberger, Maria, Hochrein, Hubertus, Melero, Ignacio, Berraondo, Pedro, Aranda, Fernando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291657/
https://www.ncbi.nlm.nih.gov/pubmed/35859732
http://dx.doi.org/10.1080/2162402X.2022.2098657

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291657/
https://www.ncbi.nlm.nih.gov/pubmed/35859732
http://dx.doi.org/10.1080/2162402X.2022.2098657

Ejemplares similares